AI IntelligenceMar 14, 2026Secondary Market
Article
ARWR
Arrowhead Pharmaceuticals (ARWR) posted first fiscal quarter 2026 revenue of $264 million. A key milestone was the approval of REDEMPLO, marking a commercial shift for the company and increasing its focus on therapy commercialization.
Data Cube AI EditorialSource: Yahoo Finance
01
Source Brief
Arrowhead Pharmaceuticals (ARWR) posted first fiscal quarter 2026 revenue of $264 million. A key milestone was the approval of REDEMPLO, marking a commercial shift for the company and increasing its focus on therapy commercialization.
02